...
首页> 外文期刊>Personalized medicine >Human pluripotent stem cells in pharmacological and toxicological screening: new perspectives for personalized medicine
【24h】

Human pluripotent stem cells in pharmacological and toxicological screening: new perspectives for personalized medicine

机译:人多能干细胞在药理和毒理学筛选中的作用:个性化医学的新观点

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Human stem cells provide an important novel tool for generating in vitro pharmacological and toxicological test systems. In the development of new targeted therapies, as well as in critical safety issues, including hepato-, neuro- and cardio-toxicity, animal-based tests are mostly unsatisfactory, whereas the use of in vitro model systems is limited by the unavailability of relevant human tissues. Human embryonic stem cell lines may fill this gap and offer an advantage over primary cultures as well as tissue-derived (adult) stem cells. Human embryonic stem cells represent an unlimited source for the production of differentiated somatic progenies and allow various stable genetic manipulations. As a new opening in personalized medicine test systems, the generation of induced pluripotent stem cell lines and their derivatives can provide patient- and disease-specific cellular assays for drug development and safety assessments. This article reviews promising human stem cell applications in pharmacological and toxicological screenings, focusing on the implications for personalized medicine.
机译:人干细胞为产生体外药理和毒理学测试系统提供了重要的新颖工具。在开发新的靶向疗法以及关键的安全问题(包括肝毒性,神经毒性和心脏毒性)中,基于动物的测试大多不尽人意,而体外模型系统的使用受限于相关模型的可用性。人体组织。人类胚胎干细胞系可能填补了这一空白,并提供了优于原代培养以及组织来源(成人)干细胞的优势。人类胚胎干细胞代表了分化体细胞后代生产的无限来源,并允许进行各种稳定的遗传操作。作为个性化医学测试系统的新开端,诱导型多能干细胞系及其衍生物的产生可以为患者和疾病提供特定的细胞测定,以进行药物开发和安全性评估。本文回顾了有前景的人类干细胞在药理学和毒理学筛选中的应用,重点关注个性化医学的意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号